Several once-weekly injections can promote weight loss, but doctors prescribe them for different purposes
Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding Maravais expected revenue and EBITDA performance for the full year 2026
We sat down and said, Heres our goals, heres how were going to process, heres what we can do to help advocate for patient access, heres what we can do internally to make sure we have product, and heres our deadlines, Fritzler said
The long-term goal isn't just to make the lab results look better, to lower the UACR or keep the eGFR from declining, so much as it is to save lives, hearts, and kidneys. Taking medications off-label is not a simple decision to make
Anticipated Costs Post-Approval While neither compound has reached market, pricing for similar medications provides context: Semaglutide (Wegovy) Approximately $1,300-$1,500 monthly without insurance Tirzepatide (Zepbound) Approximately $1,000-$1,200 monthly without insurance Cagrilintide and retatrutide would likely fall in similar price ranges, with combination therapy potentially costing $2,000-$3,000 monthly without insurance coverage
